172 related articles for article (PubMed ID: 10724355)
1. Short-term treatment with troglitazone decreases bone turnover in patients with type 2 diabetes mellitus.
Okazaki R; Miura M; Toriumi M; Taguchi M; Hirota Y; Fukumoto S; Fujita T; Tanaka K; Takeuchi A
Endocr J; 1999 Dec; 46(6):795-801. PubMed ID: 10724355
[TBL] [Abstract][Full Text] [Related]
2. The impact of an insulin sensitizer, troglitazone, on glucose metabolism in African Americans at risk for type 2 diabetes mellitus: a placebo-controlled, 24-month randomized study.
Schuster D; Gaillard T; Rhinesmith S; Habash D; Osei K
Metabolism; 2003 Sep; 52(9):1211-7. PubMed ID: 14506629
[TBL] [Abstract][Full Text] [Related]
3. Metabolic improvement of poorly controlled noninsulin-dependent diabetes mellitus decreases bone turnover.
Okazaki R; Totsuka Y; Hamano K; Ajima M; Miura M; Hirota Y; Hata K; Fukumoto S; Matsumoto T
J Clin Endocrinol Metab; 1997 Sep; 82(9):2915-20. PubMed ID: 9284719
[TBL] [Abstract][Full Text] [Related]
4. Decrease in serum leptin by troglitazone is associated with preventing bone loss in type 2 diabetic patients.
Watanabe S; Takeuchi Y; Fukumoto S; Fujita H; Nakano T; Fujita T
J Bone Miner Metab; 2003; 21(3):166-71. PubMed ID: 12720051
[TBL] [Abstract][Full Text] [Related]
5. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group.
Kumar S; Boulton AJ; Beck-Nielsen H; Berthezene F; Muggeo M; Persson B; Spinas GA; Donoghue S; Lettis S; Stewart-Long P
Diabetologia; 1996 Jun; 39(6):701-9. PubMed ID: 8781766
[TBL] [Abstract][Full Text] [Related]
6. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group.
Ghazzi MN; Perez JE; Antonucci TK; Driscoll JH; Huang SM; Faja BW; Whitcomb RW
Diabetes; 1997 Mar; 46(3):433-9. PubMed ID: 9032099
[TBL] [Abstract][Full Text] [Related]
7. Deterioration of glycemic control after long-term treatment with troglitazone in nonobese type 2 diabetic patients.
Murase Y; Wakasugi T; Yagi K; Mabuchi H
Diabetes Care; 2000 Jan; 23(1):131-2. PubMed ID: 10857989
[No Abstract] [Full Text] [Related]
8. Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy.
Iwamoto Y; Kosaka K; Kuzuya T; Akanuma Y; Shigeta Y; Kaneko T
Diabetes Care; 1996 Feb; 19(2):151-6. PubMed ID: 8718436
[TBL] [Abstract][Full Text] [Related]
9. Serum leptin level as an indicator to predict the clinical efficacy of troglitazone in patients with type 2 diabetes mellitus.
Maruyama S; Yanagisawa K; Kanamuro R; Teno S; Iwamoto Y
Diabetes Res Clin Pract; 2001 Sep; 53(3):161-4. PubMed ID: 11483231
[TBL] [Abstract][Full Text] [Related]
10. Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. The Troglitazone Study Group.
Horton ES; Whitehouse F; Ghazzi MN; Venable TC; Whitcomb RW
Diabetes Care; 1998 Sep; 21(9):1462-9. PubMed ID: 9727892
[TBL] [Abstract][Full Text] [Related]
11. Troglitazone, an antidiabetic drug, improves left ventricular mass and diastolic function in normotensive diabetic patients.
Hirayama H; Sugano M; Abe N; Yonemoch H; Makino N
Int J Cardiol; 2001 Jan; 77(1):75-9. PubMed ID: 11150629
[TBL] [Abstract][Full Text] [Related]
12. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group.
Schwartz S; Raskin P; Fonseca V; Graveline JF
N Engl J Med; 1998 Mar; 338(13):861-6. PubMed ID: 9516220
[TBL] [Abstract][Full Text] [Related]
13. Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. The Troglitazone Study Group.
Fonseca VA; Valiquett TR; Huang SM; Ghazzi MN; Whitcomb RW
J Clin Endocrinol Metab; 1998 Sep; 83(9):3169-76. PubMed ID: 9745421
[TBL] [Abstract][Full Text] [Related]
14. Troglitazone reduces plasma leptin concentration but increases hunger in NIDDM patients.
Shimizu H; Tsuchiya T; Sato N; Shimomura Y; Kobayashi I; Mori M
Diabetes Care; 1998 Sep; 21(9):1470-4. PubMed ID: 9727893
[TBL] [Abstract][Full Text] [Related]
15. A pilot clinical trial of a new oral hypoglycemic agent, CS-045, in patients with non-insulin dependent diabetes mellitus.
Kuzuya T; Iwamoto Y; Kosaka K; Takebe K; Yamanouchi T; Kasuga M; Kajinuma H; Akanuma Y; Yoshida S; Shigeta Y
Diabetes Res Clin Pract; 1991 Mar; 11(3):147-53. PubMed ID: 2036936
[TBL] [Abstract][Full Text] [Related]
16. Effect of troglitazone on endothelial function in type 2 diabetic patients.
Takase H; Hakamata M; Toriyama T; Hayashi K; Gotoa T; Sato K; Ueda R; Dohi Y
Arzneimittelforschung; 2002; 52(1):34-8. PubMed ID: 11838272
[TBL] [Abstract][Full Text] [Related]
17. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial.
Yale JF; Valiquett TR; Ghazzi MN; Owens-Grillo JK; Whitcomb RW; Foyt HL
Ann Intern Med; 2001 May; 134(9 Pt 1):737-45. PubMed ID: 11329231
[TBL] [Abstract][Full Text] [Related]
18. Troglitazone decreases serum uric acid concentrations in type II diabetic patients and non-diabetics.
Iwatani M; Wasada T; Katsumori K; Watanabe-Takahashi C; Kamatani N; Iwamoto Y
Diabetologia; 2000 Jun; 43(6):814-5. PubMed ID: 10907128
[No Abstract] [Full Text] [Related]
19. Effects of troglitazone in patients with type 2 diabetes mellitus not adequately controlled by sulfonylureas.
Bunnag P; Puavilai G; Chanprasertyotin S; Chandraprasert S; Suwanwalaikorn S; Suthijumroon A; Benjasuratwong Y; Boonyavarakul A; Nitiyanant W; Sriussadaporn S; Deerochanawong C;
Diabetes Res Clin Pract; 2001 Feb; 51(2):151-3. PubMed ID: 11253769
[No Abstract] [Full Text] [Related]
20. Effect of troglitazone in type 2 diabetes mellitus.
Gorson DM
N Engl J Med; 1998 Aug; 339(6):406. PubMed ID: 9696655
[No Abstract] [Full Text] [Related]
[Next] [New Search]